Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 6 more changesShow less
    • Start date: Sep 1, 2026 to Nov 1, 2026
    • Eligibility criteria expanded, about 97 words
    • Secondary endpoints: details revised at 1 of 7 entries
    • Study description revised
    • Site details revised
    • Collaborators: details revised at 1 of 1 entry
  2. Start date: May 1, 2026 to Sep 1, 2026v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This phase II trial tests how well nemtabrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cells (a type of white blood cell) in cancers such as CLL or SLL at abnormal levels. This may help keep cancer cells from growing and spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Giving nemtabrutinib in combination with venetoclax may kill more cancer cells in patients with CLL or SLL.
Trial Details
NCT Number NCT07557056
Lead Sponsor Jennifer Woyach
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Related terms Leukemia, Lymphocytic, Chronic, B-Cell
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov